Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474393 | 0.98 | SCN10A (0.53) | SCN10ATRPV1TLR7 | |
| SCHEMBL4000217 | 0.86 | TRPV1 (0.47) | SCN10ATRPV1 | |
| SCHEMBL31037416 | 0.86 | SCN10A (0.58) | SCN10A | |
| SCHEMBL23779545 | 0.85 | SCN10A (0.42) | SCN10ATRPV1MAPK1 | |
| SCHEMBL3940573 | 0.81 | SCN10A (0.52) | SCN10ATRPV1MAPK1HSD17B10 | |
| SCHEMBL3940771 | 0.79 | SCN10A (0.48) | SCN10ATRPV1HSD17B10 | |
| SCHEMBL15351260 | 0.79 | L3MBTL1 (0.46) | SCN10AMAPK1TLR7 | |
| SCHEMBL3946526 | 0.78 | SCN10A (0.45) | SCN10ATRPV1MAPK1HSD17B10 | |
| SCHEMBL3946543 | 0.78 | SCN10A (0.45) | SCN10ATRPV1MAPK1HSD17B10 | |
| SCHEMBL23981524 | 0.77 | GABRP (0.49) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | SCN10A 402/4885TRPV1 2741/4885MAPK1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.